NCT07216859View on ClinicalTrials.gov

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

NANot yet recruitingINTERVENTIONAL
Enrollment

2,000

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2027

Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver DiseaseCirrhosis
Interventions
OTHER

AI-Enabled Identification (EchoNet-Liver)

AI-generated notifications to clinicians about possible undiagnosed liver disease (MASLD and/or Cirrhosis) detected from Transthoracic Echocardiogram

Trial Locations (4)

90034

Cedars-Sinai Medical Center, Los Angeles

94588

Stanford Healthcare, Palo Alto

Kaiser Permanente, Pleasanton

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Stanford University

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

Cedars-Sinai Medical Center

OTHER

lead

Kaiser Permanente

OTHER

NCT07216859 - Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI) | Biotech Hunter | Biotech Hunter